Doha, May 13 (QNA) - Sidra Medicine, a member of Qatar Foundation, has been formally designated as a ZEISS labs@location Reference Customer through its Advanced Imaging Core (AIC).

The designation places Sidra Medicine among a select international network of research hospitals, academic medical centers, and core facilities recognized for excellence in advanced microscopy and imaging technologies.

The ZEISS labs@location Program is designed to strengthen collaboration between ZEISS and leading laboratories worldwide by supporting the development of imaging applications, scientific training, expert demonstrations, and knowledge exchange.

Lead, Advanced Imaging Core at Sidra Medicine Abbirami Sathappan said: "Being recognized as a ZEISS labs@location Reference Customer reflects the strength of the expertise, infrastructure, and collaborative environment we have built within the Advanced Imaging Core. The designation strengthens our ability to support researchers and clinicians with advanced imaging workflows that accelerate discovery and contribute to clinically relevant research."

The designation was awarded following an evaluation of Sidra Medicine's Advanced Imaging Core, which demonstrated advanced imaging capabilities, strong operational standards, scientific expertise, and the ability to provide high-level training and knowledge transfer. The center was also recognized for its ability to support complex imaging applications, publication-grade research, and collaborative scientific initiatives.

Through the designation, Sidra Medicine joins an elite group of institutions selected based on scientific excellence and innovation, placing the organization alongside globally recognized leaders in imaging science and biomedical research.

Chief Research Officer at Sidra Medicine Prof. Khalid Fakhro said: "We are very proud today of this exceptional recognition of our Advanced Imaging Core. At Sidra Medicine, our philosophy has always been to invest in developing state-of-the-art core research platforms, led by visionary staff building testing capabilities with direct relevance for patient care.

This designation by Zeiss underscores our mission to advance diagnostics and mechanistic understanding of rare and complex diseases, which ultimately translates to more precise treatment and improved outcomes for patients." (QNA)